OTTAWA, Ontario--(BUSINESS WIRE)--Oct. 22, 2012--
Nordion Inc. (TSX: NDN) (NYSE: NDZ) extended its contract with its
primary Medical Isotopes customer, Lantheus Medical Imaging, Inc. (LMI)
for the supply of Molybdenum-99
(Mo-99).
Under the terms of the amended agreement, the contract has been extended
for an additional two years through 2015. Nordion expects to supply
Mo-99 on a weekly basis to Lantheus Medical Imaging. The multi-year
contract reflects specific pricing for each year of the contract.
Lantheus is Nordion’s single largest customer, purchasing the majority
of Nordion’s Mo-99.
"Lantheus is a world leader in securing and supplying Mo-99. This
multi-year agreement with Nordion underlines our commitment to serving
the global nuclear medicine community through a diversified and balanced
supply chain for Mo-99," said Don Kiepert, President and Chief Executive
Officer, Lantheus Medical Imaging, Inc. “We look forward to this
continuation of our long-standing relationship with Nordion.”
"We are pleased to extend our contract with Lantheus. This agreement
provides Nordion with additional clarity of the multi-year demand for
our Mo-99,” said Steve West, Chief Executive Officer, Nordion. “Both
Nordion and Lantheus continue to be important participants in the global
supply chain for Mo-99 which is so critical to physicians and patients
worldwide.”
Medical isotopes are used by physicians to diagnose and treat a number
of diseases, including cardiac and neurological conditions, and several
types of cancer. Mo-99, and more specifically the derivative medical
isotope technetium-99m, is utilized in approximately 80 per cent of
nuclear medical procedures worldwide.
Forward Looking Statements
Certain statements contained in this news release constitute
"forward-looking statements". These statements are based on current
beliefs and assumptions of management, however are subject to known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially from the forward-looking statements in this
news release. For additional information with respect to certain of
these beliefs, assumptions, risks and uncertainties, please refer to
Nordion’s Annual Information Form for fiscal 2011 available on SEDAR at www.sedar.com
and on EDGAR on www.sec.gov.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing,
manufacturing and distributing innovative diagnostic imaging agents, is
dedicated to creating and providing pioneering medical imaging solutions
to improve the treatment of human disease. The Company’s proven success
in the field of diagnostic imaging provides a strong platform from which
to bring forward breakthrough new tools for the diagnosis and management
of disease. Lantheus imaging products include the echocardiography
contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere)
Injectable Suspension, an ultrasound contrast agent for use in patients
with suboptimal echocardiograms to opacify the left ventricular chamber
and to improve the delineation of the left ventricular endocardial
border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic
resonance agent indicated for the evaluation of aortoiliac occlusive
disease in adults with known or suspected peripheral vascular disease,
TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the
Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium
201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600
employees worldwide with headquarters in North Billerica, Massachusetts,
and offices in Puerto Rico, Canada and Australia. For more information,
visit www.lantheus.com.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention, diagnosis
and treatment of disease. We are a leading provider of medical isotopes,
targeted therapies and sterilization technologies that benefit the lives
of millions of people in more than 60 countries around the world. Our
products are used daily by pharmaceutical and biotechnology companies,
medical-device manufacturers, hospitals, clinics and research
laboratories. Nordion has approximately 500 highly skilled employees in
four locations. Find out more at www.nordion.com
and follow us at http://twitter.com/NordionInc
Source: Nordion
Nordion
Media:
Tanya Pobuda, 613-592-3400 x. 2280
tanya.pobuda@nordion.com
or
Investors:
Tamra
Benjamin, 613-592-3400 x. 1022
investor.relations@nordion.com
